Evidence map›Paper›PMID 42073575›Full record

ArticleCancers2026

Comparative Preclinical Evaluation of BIX-01294 and UNC0642 as EHMT2-Targeting Anticancer Agents.

Sang Eun Park, Ji-Yoon Lee, Unju Lee, Seoyeong Kim, Nok Bi Lee, Eun Jin Cho, Seong-Yun Jeong, Soo Jin Oh, Jung Jin Hwang

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sang Eun ParkAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
Ji-Yoon LeeAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
Unju LeeAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0002-1673-555X
Seoyeong KimAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
Nok Bi LeeDepartment of Medicine, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Eun Jin ChoDepartment of Medicine, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Seong-Yun JeongAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0003-0959-5488
Soo Jin OhAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
Jung Jin HwangAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0003-0912-1055

Funding

Asan Medical Center 2023IP0102Asan Medical Center 2023IP0119Korea Drug Development Fund HN22C0033Korea Health Industry Development Institute RS-2023-00261982
6 · The paper itself

Abstract

backgroundEHMT2 (G9a) is a key epigenetic regulator frequently overexpressed in various cancers. While several inhibitors exist, their in vivo efficacy and pharmacokinetic (PK) properties remain poorly characterized.

methodsWe compared the biochemical, cellular, and PK profiles of two widely used EHMT2 inhibitors, BIX-01294 and UNC0642, and evaluated their antitumor efficacy in xenograft and syngeneic mouse models.

resultsDespite a higher enzymatic potency of UNC0642 (

conclusionsThese results suggest that BIX-01294 is more effective in vivo than UNC0642 due to its favorable PK profile and superior cellular uptake. Our findings support the further development of EHMT2 inhibitors as potent partners for immune checkpoint blockades.

Indexed as

anti-PD-L1BIX-01294EHMT2G9aimmune checkpoint blockadepharmacokineticsUNC0642

Identifiers

PMID42073575
PMCPMC13115232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.